Posted by MD Biosciences on Sep 29, 2020 3:51:28 PM
Topics: preclinical research, COVID-19
Posted by MD Biosciences on Sep 15, 2020 11:39:11 AM
Our team is excited to announce that we have signed an agreement in partnership with IncellDx, Inc., a global leader in single-cell diagnostics, to evaluate therapeutic biomarkers in COVID-19 and other cytokine storm conditions.
With our esoteric immune-based testing, we will validate and offer lab testing in the United States and European Union to measure levels of COVID/cytokine storm-related therapeutics. "Such cytokines are significantly elevated in patients with COVID-19, and usually remain abnormal in recovering patients, but still are suffering from symptoms. These patients are referred to as 'long-haulers' (PR News Centre, 2020)".
To read the full article published by PR News Centre, follow the link below and learn more.
How can MD Biosciences support your clinical programs? Please contact our team with any questions, we are happy to speak with you!
+1 (651) 641-1770
Topics: Inflammation, Biomarkers, Personalized medicine, CLIA, Cytokines, clinical research, clinical diagnostics, COVID-19
Posted by MD Biosciences on Sep 3, 2020 10:15:00 AM
We are happy to announce that we have established MD Biosciences Neuro, LLC. in Cambridge, Massachusetts to expand our work and collaborations in the United States. Our team, led by Chief Scientific Officer, Sigal Meilin, is looking forward to developing close partnerships with you and continuing to advance the field of neurology and pain research.
With a multifaceted approach to assessment of neurological diseases, specializations include pain-related work, neurodegenerative diseases including Parkinson's, neuro-inflammatory diseases such as Multiple Sclerosis (MS), and capabilities in stroke and cerebral ischemia. Preclinical models are complimented by in house histology, biomarker analysis and electrophysiology capabilities. Finally, our unique porcine models share a high degree of similarity to humans, thus offering greater clinical efficacy that serve to augment and accelerate your program towards their next objectives and milestones.
Please contact us with any questions about our services, capabilities, and customizable study design options.
Topics: Pain, news, Neuro/CNS, Preclinical Discovery, neuropathic pain, Life Science, translational, assays, drug development, preclinical research, disease models, Biotechnology, Behavioral Research, porcine model, Neuroscience
Posted by MD Biosciences on Sep 2, 2020 12:15:08 PM
We are happy to announce that we have established MD Biosciences Bioproducts, LLC. in Oakdale, Minnesota to expand our work and collaborations worldwide. Our team is dedicated to the development, manufacturing and distribution of life science research products suited for inflammatory and autoimmune diseases, neurology, oncology, pain, and metabolism.
It is our goal to collaborate with pharmaceutical, biotech, academic and government communities to provide you with the tools needed to optimize your research process enabling you to reach your objectives faster. We offer antibodies, reagents and assays for use in various therapeutic areas of research.
Please contact us with any questions about our products and capabilities.
Topics: news, Research Products, Preclinical Discovery, Life Science, assays, drug development, clinical research, Biotechnology